Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials

By sjmartinez • January 17, 2024

Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials. Br J Dermatol. 2024 Jan 16:ljae014. doi: 10.1093/bjd/ljae014. Epub ahead of print. PMID: 38226713.

Tags: Dermatology, Olive View DoM, Publications

The Association between Obesity and Efficacy of Psoriasis Therapies: An Expert Consensus Panel

Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb AB, Gold LS, Korman NJ, Lio P, Merola J, Rosmarin D, Rosenberg A, Van[...]

Increased mitochondrial mutation heteroplasmy induces aging phenotypes in pluripotent stem cells and their differentiated progeny

Vandiver AR, Torres A Jr, Sanden A, Nguyen TL, Gasilla J, Doan MT, Martirosian V, Hoang A, Wanagat J, Teitell MA. Increased mitochondrial mutation heteroplasmy[...]

Update on Absorbable Facial Thread Lifts

Riopelle AM, Geisler AN, Eber A, Dover JS. Update on Absorbable Facial Thread Lifts. Dermatol Surg. 2024 Dec 11. doi: 10.1097/DSS.0000000000004521. Epub ahead of print.[...]